（来源：湖州日报） 转自：湖州日报 信中提及的，是一名因重症肺炎导致心、肺、肾等多脏器衰竭的年轻患者。当时，患者已陷入深度昏 迷、"白肺"、呼吸机下氧合不能维持、休克，生命体征极度不稳。谢波团队果断决策，启用代表顶尖生 命支持技术的ECMO（体外膜肺氧合）与CRRT（连续性肾脏替代治疗）等联合救治，支撑和维护患者 衰竭的心肺与肾脏及内环境功能，为受损脏器赢得了宝贵的自我修复机会和时间。 记者 张 璐 "在这与生命赛跑的20多个日日夜夜里，你们全力以赴、不辞劳苦、夜以继日；在我儿子生命垂危之 际，你们不放弃、不抛弃……生命的使者，你们最美。"这封手写的感谢信，被市急危重症医学中心 （重症方向）执行主任、湖州市中心医院重症医学科学科带头人谢波珍藏着。 "当多脏器衰竭这类最棘手的危重症来临时，我们能迅速打破专科壁垒，变分力为合力，启动'心—肺— 肾—肝'全方位的集束化支持。"谢波介绍，对于暴发性心肌炎、重症急性心肌梗死、重症肺炎、脓毒症 休克等危重症，中心已常规化开展ECMO、IABP（主动脉内球囊反搏）、多种模式CRRT以及重症超声 等技术的组合应用，形成了一套成熟的"重症救治技术包"。 在谢波看来，拥有ECMO ...

（来源：湖州日报） 转自：湖州日报 记者 张璐 "心脏反复停跳63次！每一次停跳，我们都是在和死神抢人！"近日，回想起那场惊心动魄的抢救，市急 危重症医学中心（重症方向）执行主任、市中心医院重症医学科学科带头人谢波依然印象深刻。 此前，一名50岁的暴发性心肌炎患者被送入医院。在急诊和重症病房内，他的心脏如同失控的引擎，室 颤、室速反复发作。谢波果断启动VA-ECMO（体外循环膜肺氧合）进行体外生命支持，即ECPR（体 外心肺复苏），电除颤与医护人员的持续胸外按压交替进行……他们的不放弃，换来了生命的奇迹，5 天后，患者成功撤除ECMO；1个月后，完全康复出院。 "ECMO是力挽狂澜的'终极武器'，但更多时候，我们还是要用小技术来解决大难题。"谢波介绍，近 期，一名32岁的重症心肌炎合并心源性休克患者从外院转来，当地医院已准备上ECMO抢救。谢波团队 综合评估后，决定先采用创伤更小、成本更低的IABP（主动脉内球囊反搏）联合呼吸机支持。他解释 说，IABP就像给衰弱的心脏配一个"助力泵"，不同选择，体现的是重症救治理念的成熟——以最小损 伤、最优成本为患者赢得生机和以后的生活质量。 谢波表示，该院作为市急危重症 ...

Core Viewpoint - MicroPort Medical announced the approval of a strategic merger between MicroPort Cardiac and MicroPort Rhythm Management, aiming to integrate their core business segments of structural heart disease and rhythm management, thereby enhancing comprehensive heart failure management solutions [2][3]. Group 1: Merger Details - The merger will enable the creation of a comprehensive management solution for heart failure, covering all causes, stages, and processes, including monitoring, diagnosis, treatment, and management [2][3]. - MicroPort Cardiac has established a leading position in the domestic market for transcatheter aortic valve implantation (TAVI) products, with the highest implantation volume [2]. - The company is advancing a new generation of innovative pipelines, including products for mitral and tricuspid valves, surgical support products, and interventricular septal reconstruction products, while also accelerating overseas market expansion [2]. Group 2: Product and Market Strategy - MicroPort Rhythm Management is one of the few companies globally with a complete product line for rhythm management, including pacemakers, implantable cardioverter-defibrillators (ICDs), cardiac resynchronization therapy devices (CRT-Ds), leads, and monitoring equipment [3]. - The merged entity will leverage its product layout in structural heart disease, rhythm management, and heart failure to provide a comprehensive management solution for heart failure [3]. - The first heart failure product, an intra-aortic balloon pump (IABP), is expected to be approved in China by 2026, indicating a push towards commercializing heart failure management [3]. Group 3: Operational Synergies - Post-merger, the integration of channels, registration, and logistics systems is expected to facilitate faster market entry for structural heart disease products through the rhythm management platform [4]. - The combination of structural products with rhythm management offerings will enhance sales efficiency and marketing effectiveness in the domestic market [4].